title: A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
abstract: OBJECTIVE
  To examine the long-term outcomes of a randomized trial comparing short (4 months; Arm 1) and long (8 months; Arm 2) neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
  
  
  METHODS
  Between 1997 and 2001, 276 patients were enrolled and the data from 261 were analyzed. The stratification risk factors were prostate-specific antigen level >20 ng/mL, Gleason score≥7, and Stage T3 or more. The intermediate-risk stratum had one factor and the high-risk stratum had two or more. Staging was done from the bone scan and computed tomography findings. The primary endpoint was biochemical failure-free survival.
  
  
  RESULTS
  The median follow-up was 102 months. The overall survival, biochemical failure-free survival. and prostate cancer-specific survival did not differ significantly between the two treatment arms, overall or at 5 years. The cumulative probability of overall survival at 5 years was 90% (range, 87-92%) in Arm 1 and 83% (range, 80-86%) in Arm 2. The biochemical failure-free survival rate at 5 years was 66% (range, 62-71%) in Arm 1 and 63% (range, 58-67%) in Arm 2.
  
  
  CONCLUSIONS
  No statistically significant difference was found in biochemical failure-free survival between 4 months and 8 months of neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
authors.affiliation: Department of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland.
authors.forename: John G
authors.initials: JG
authors.lastname: Armstrong
authors.forename: Charles M
authors.initials: CM
authors.lastname: Gillham
authors.forename: Mary T
authors.initials: MT
authors.lastname: Dunne
authors.forename: David A
authors.initials: DA
authors.lastname: Fitzpatrick
authors.forename: Marie A
authors.initials: MA
authors.lastname: Finn
authors.forename: Mairín E
authors.initials: ME
authors.lastname: Cannon
authors.forename: Judy C
authors.initials: JC
authors.lastname: Taylor
authors.forename: Carmel M
authors.initials: CM
authors.lastname: O'Shea
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Buckney
authors.forename: Pierre G
authors.initials: PG
authors.lastname: Thirion
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging / Q000379:methods; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D020266:Radiotherapy, Conformal / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D005485:Flutamide; D017430:Prostate-Specific Antigen